1
SECURITIES EXCHANGE AND COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): September 30, 1997
ARADIGM CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 0-28402 94-3133088
- ------------- ---------------- -------------------
State of (Commission File (IRS Employer
Incorporation Number) Identification No.)
26219 Eden Landing Road, Hayward, California 94545
--------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(510) 783-0100
----------------------------------------------------
(Registrant's telephone number, including area code)
2
Item 5. Other Events.
------------
On September 30, 1997, the Registrant entered into a Product
Development and Commercialization Agreement (the "Agreement") with SmithKline
Beecham PLC ("SmithKline") for the purpose of developing and commercializing a
pulmonary drug delivery system for providing immediate pain relief using
opiates and opioids. In connection with the Agreement, the Registrant entered
into a Stock Purchase Agreement with SmithKline, pursuant to which the
Registrant sold and issued 405,064 shares of the Registrant's Common Stock to
SmithKline at an aggregate purchase price of $5,000,008.75.
Item 7. Exhibits.
--------
+10.1 Product Development and Commercialization Agreement between
the Registrant and SmithKline Beecham PLC.
+10.2 Stock Purchase Agreement between the Registrant and SmithKline
Beecham PLC.
- ----------------------------
+Confidential treatment requested.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ARADIGM CORPORATION
/s/ Richard P. Thompson
-------------------------
Dated: November 6, 1997 Richard P. Thompson
President and Chief Executive Officer
4
INDEX TO EXHIBITS
Page number in
sequentially
numbered version
----------------
+10.1 Product Development and Commercialization Agreement
between the Registrant and SmithKline Beecham PLC.
+10.2 Stock Purchase Agreement between the Registrant
and SmithKline Beecham PLC.
- ---------------------
+Confidential treatment requested.